{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011892","form_type":"8-K/A","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.687106+00:00","generated_at":"2026-06-17T03:06:33.861308+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Biosciences issues $769K convertible notes and warrants for ~$490K net","bullets":["Aggregate $769,230.76 in senior subordinate convertible notes issued to investors.","Warrants to purchase 76,923,077 shares of common stock issued.","Investors paid $650 per $1,000 principal amount (~35% discount).","Net proceeds to company after expenses approximately $490,000.","Offering closed April 5, 2023; this 8-K/A corrects a typo in the original report."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011892","json":"https://secwatch.observer/filing/0001493152-23-011892.json","markdown":"https://secwatch.observer/filing/0001493152-23-011892.md","text":"https://secwatch.observer/filing/0001493152-23-011892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/0001493152-23-011892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:06:33.861308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6518c8f80ad2d383d87e41c7073e75c55dc4845d","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $769,230.76 (effective 2023-04-05).","evidence_excerpt":"On April 5, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”) entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $769,230.76","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223011892/0001493152-23-011892-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$769,230.76"},{"label":"Effective","value":"2023-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}